|Other Names||Cofilin-2, Cofilin, muscle isoform, CFL2|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP14117a was selected from the N-term region of CFL2. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Controls reversibly actin polymerization and depolymerization in a pH-sensitive manner. Its F-actin depolymerization activity is regulated by association with CSPR3 (PubMed:19752190). It has the ability to bind G- and F-actin in a 1:1 ratio of cofilin to actin. It is the major component of intranuclear and cytoplasmic actin rods. Required for muscle maintenance. May play a role during the exchange of alpha-actin forms during the early postnatal remodeling of the sarcomere (By similarity).|
|Cellular Location||Nucleus matrix. Cytoplasm, cytoskeleton. Note=Colocalizes with CSPR3 in the Z line of sarcomeres.|
|Tissue Location||Isoform CFL2b is expressed predominantly in skeletal muscle and heart. Isoform CFL2a is expressed in various tissues|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
This gene encodes an intracellular protein that isinvolved in the regulation of actin-filament dynamics. This proteinis a major component of intranuclear and cytoplasmic actin rods. Itcan bind G- and F-actin in a 1:1 ratio of cofilin to actin, and itreversibly controls actin polymerization and depolymerization in apH-dependent manner. Mutations in this gene cause nemaline myopathytype 7, a form of congenital myopathy. Alternative splicing resultsin multiple transcript variants.
Vogel, S., et al. J. Biol. Chem. 285(44):33756-33763(2010)Borensztajn, K., et al. Thromb. Res. 125 (6), E323-E328 (2010) :Papalouka, V., et al. Mol. Cell. Biol. 29(22):6046-6058(2009)Wu, Y., et al. Retrovirology 5, 95 (2008) :Agrawal, P.B., et al. Am. J. Hum. Genet. 80(1):162-167(2007)
If you have any additional inquiries please email technical services at firstname.lastname@example.org.